Hookipa Pharma (HOOK) Competitors

Lantern Pharma (NASDAQ:LTRN) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.

Does the media prefer LTRN or HOOK?

In the previous week, Lantern Pharma had 2 more articles in the media than Hookipa Pharma. MarketBeat recorded 6 mentions for Lantern Pharma and 4 mentions for Hookipa Pharma. Lantern Pharma's average media sentiment score of 0.96 beat Hookipa Pharma's score of 0.47 indicating that Hookipa Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hookipa Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in LTRN or HOOK?

Hookipa Pharma received 72 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 80.00% of users gave Lantern Pharma an outperform vote while only 68.85% of users gave Hookipa Pharma an outperform vote.

Company	Underperform	Outperform
Lantern Pharma	Outperform Votes 12 80.00%	Underperform Votes 3 20.00%
Hookipa Pharma	Outperform Votes 84 68.85%	Underperform Votes 38 31.15%

Do analysts rate LTRN or HOOK?

Hookipa Pharma has a consensus price target of $5.17, indicating a potential upside of 537.86%. Given Lantern Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Hookipa Pharma is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hookipa Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders believe in LTRN or HOOK?

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are owned by institutional investors. 6.9% of Lantern Pharma shares are owned by company insiders. Comparatively, 4.6% of Hookipa Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has more risk and volatility, LTRN or HOOK?

Lantern Pharma has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Is LTRN or HOOK more profitable?

Lantern Pharma has a net margin of 0.00% compared to Lantern Pharma's net margin of -405.28%. Hookipa Pharma's return on equity of -34.11% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-34.11%	-32.19%
Hookipa Pharma	-405.28%	-72.30%	-40.51%

Which has preferable valuation and earnings, LTRN or HOOK?

Lantern Pharma has higher earnings, but lower revenue than Hookipa Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$15.96M	-$1.48	-4.09
Hookipa Pharma	$20.13M	3.98	-$81.58M	-$0.88	-0.92

Summary

Hookipa Pharma beats Lantern Pharma on 9 of the 17 factors compared between the two stocks.